EGFR;Epidermal growth factor receptor;Proto-oncogene c-ErbB-1;Receptortyrosine-protein kinase erbB-1

HEK293 Cells

Leu25-Ser378

NP_001333870

Human

41.5 kDa

60-90 kDa

C-His-Avi

Not validated for activity

> 95 % as determined by reducing SDS-PAGE.

< 1.0 EU per μg of the protein as determined by the LAL method.

Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

This product is provided as lyophilized powder which is shipped with ice packs.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Please refer to the printed manual for detailed information.

The EGFR subfamily of receptor tyrosine kinases is composed of EGFR; ErbB2; ErbB3 and ErbB4. The EGFR shares 43% - 44% aa sequence identity with the ECD of human EGFR subfamily. All these family members are type I transmembrane glycoproteins with an extracellular ligand binding domain. The extracellular ligand binding domain is containing two cysteine-rich domains separated by a spacer region and a cytoplasmic domain containing a membrane-proximal tyrosine kinase domain. Ligand binding could induce EGFR homodimerization and heterodimerization with ErbB2; resulting in cell signaling; heterodimerization tyrosine phosphorylation and kinase activation. It can bind EGF; amphiregulin; TGF-alpha; betacellulin; epiregulin; HB-EGF; epigen; and so on. Its signaling regulates multiple biological functions including cell proliferation; differentiation; motility; and apoptosis. EGFR can also be recruited to form heterodimers with the ligand-activated ErbB3 or ErbB4. EGFR is overexpressed in different tumors. Several anti-cancer drugs use EGFR as target.